In addition to strong fourth quarter earnings reported this morning, Insys Therapeutics' (NASDAQ: INSY) Board of Directors has approved a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE